Drugs.com - Clinical Trials

Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 - Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell...

Apr 30, 2025 - 22:47
 0
Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC
Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025 - Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell...
Read More

Tags:

Previous Article

Hunt for tree rings could yield Africa’s first drought atlas

Next Article

Haute Living’s Haute Leaders Dinner: A Night At Zucca Miami

Related Posts

Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

Chlamydia Vaccine Candidate Granted Fast Track Designat...

Apr 26, 2025  0

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences Receives U.S. FDA Fast Track Desi...

Apr 26, 2025  0

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant Announces Positive Results for Batoclimab My...

Apr 26, 2025  0